Ulcerative Colitis Flare
7
1
3
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (7)
Transfer of Feces in Ulcerative Colitis 2
MARVEL: Mitochondrial Anti-oxidant Therapy to Resolve Inflammation in Ulcerative Colitis
Maresin-1 and Resolvin-D1 Levels and Disease Activity in Ulcerative Colitis
Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC)
Screening Donors, Fecal Microbiota Transplant Program in Ulcerative Colitis
Local and Systemic Immunoprofiling of Patients Diagnosed With Ulcerative Colitis
Lactobacillus Reuteri ATCC PTA 4659 in Ulcerative Colitis